Latest news and insights on the pharmaceutical industry | Indian Pharma Post

Results For "Johnson-&-Johnson"

27 News Found

Johnson & Johnson MedTech India partners with Karkinos to upskill professionals in cancer care
Healthcare | February 13, 2023

Johnson & Johnson MedTech India partners with Karkinos to upskill professionals in cancer care

To bring quality cancer treatment closer to patients, India’s leading MedTech brand is joining forces with the unique technology-led platform


Johnson & Johnson and Momenta Pharmaceuticals file lawsuit against NATCO Pharma
News | May 25, 2022

Johnson & Johnson and Momenta Pharmaceuticals file lawsuit against NATCO Pharma

This lawsuit has been filed in the Pennsylvania Federal Court. NATCO and its marketing partner Mylan


Johnson & Johnson India launches ‘Be The Change For TB’ initiative
Public Health | March 24, 2022

Johnson & Johnson India launches ‘Be The Change For TB’ initiative

#BeTheChangeForTB is a public awareness initiative under the Corporate TB Pledge and aims to create a cadre of Youth Changemakers who can act as catalysts of change to help eliminate TB from India


Johnson & Johnson Vision Care receives USFDA approval for drug-eluting contact lens
Drug Approval | March 06, 2022

Johnson & Johnson Vision Care receives USFDA approval for drug-eluting contact lens

Novel technology combines ACUVUE daily disposable contact lenses with an established antihistamine in FDA- first in its new category


Lancet study confirms Johnson & Johnson Ebola vaccine safe
Drug Approval | September 16, 2021

Lancet study confirms Johnson & Johnson Ebola vaccine safe

Data show the vaccine regimen induced neutralising antibody responses in nearly all participating adults and children 21 days after the second dose. Adults receiving booster shots two years after the initial vaccination regimen showed strong immune responses


Johnson & Johnson booster dose indicate impressive results
Drug Approval | August 26, 2021

Johnson & Johnson booster dose indicate impressive results

New interim data from these studies demonstrate that a booster dose of the Johnson & Johnson Covid-19 vaccine generated a rapid and robust increase in spike-binding antibodies, nine-fold higher than 28 days after the primary single-dose vaccination.


Johnson & Johnson single-shot COVID-19 vaccine granted emergency use listing by WHO
News | March 15, 2021

Johnson & Johnson single-shot COVID-19 vaccine granted emergency use listing by WHO

The vaccine was 85 percent effective in preventing severe disease across all regions.


Biocon Biologics secures US market entry date for Bmab 1200
Drug Approval | March 01, 2024

Biocon Biologics secures US market entry date for Bmab 1200

The agreement licenses the company to launch in the United States, in February 2025, once approved by the U.S. FDA


Bausch + Lomb acquires Blink eye drops
Healthcare | July 11, 2023

Bausch + Lomb acquires Blink eye drops

The strategic acquisition demonstrates the company’s commitment to increasing OTC consumer convenience in eye care